IL201104A - Compound 3-Amido-Pyrolo [3,4- c] Phospholase-5 (h1, h4, h6) Carbaldehyde for use as a protein kinase c inhibitor, a pharmaceutical composition comprising the compound and the use of a compound in the preparation of a drug - Google Patents

Compound 3-Amido-Pyrolo [3,4- c] Phospholase-5 (h1, h4, h6) Carbaldehyde for use as a protein kinase c inhibitor, a pharmaceutical composition comprising the compound and the use of a compound in the preparation of a drug

Info

Publication number
IL201104A
IL201104A IL201104A IL20110409A IL201104A IL 201104 A IL201104 A IL 201104A IL 201104 A IL201104 A IL 201104A IL 20110409 A IL20110409 A IL 20110409A IL 201104 A IL201104 A IL 201104A
Authority
IL
Israel
Prior art keywords
compound
pyrrolo
pyrazole
amido
medicament
Prior art date
Application number
IL201104A
Other languages
English (en)
Hebrew (he)
Other versions
IL201104A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL201104A0 publication Critical patent/IL201104A0/en
Publication of IL201104A publication Critical patent/IL201104A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL201104A 2007-04-12 2009-09-22 Compound 3-Amido-Pyrolo [3,4- c] Phospholase-5 (h1, h4, h6) Carbaldehyde for use as a protein kinase c inhibitor, a pharmaceutical composition comprising the compound and the use of a compound in the preparation of a drug IL201104A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91146207P 2007-04-12 2007-04-12
US3551908P 2008-03-11 2008-03-11
US4011508P 2008-03-27 2008-03-27
PCT/IB2008/000862 WO2008125945A2 (en) 2007-04-12 2008-04-10 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c

Publications (2)

Publication Number Publication Date
IL201104A0 IL201104A0 (en) 2010-05-17
IL201104A true IL201104A (en) 2017-09-28

Family

ID=39764996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201104A IL201104A (en) 2007-04-12 2009-09-22 Compound 3-Amido-Pyrolo [3,4- c] Phospholase-5 (h1, h4, h6) Carbaldehyde for use as a protein kinase c inhibitor, a pharmaceutical composition comprising the compound and the use of a compound in the preparation of a drug

Country Status (11)

Country Link
US (2) US8114871B2 (enExample)
EP (1) EP2195321B1 (enExample)
JP (1) JP5404601B2 (enExample)
KR (1) KR101113387B1 (enExample)
CN (3) CN101675052A (enExample)
AU (1) AU2008237660B2 (enExample)
CA (1) CA2683695C (enExample)
HK (1) HK1207067A1 (enExample)
IL (1) IL201104A (enExample)
MX (1) MX2009010951A (enExample)
WO (1) WO2008125945A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008125945A2 (en) 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
EP2485727A4 (en) * 2009-10-06 2013-05-01 Afraxis Inc PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES
CU24077B1 (es) * 2009-11-10 2015-03-30 Pfizer DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
CA2815169C (en) 2010-10-29 2015-10-06 Pfizer Inc. N1/n2-lactam acetyl-coa carboxylase inhibitors
EA023168B1 (ru) 2011-02-11 2016-04-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор катепсина с
ME02312B (me) 2011-04-22 2016-06-20 Pfizer DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2755652B1 (en) * 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2015179847A1 (en) * 2014-05-23 2015-11-26 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
EP3214086B1 (en) * 2014-10-31 2021-09-22 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
US20170246166A1 (en) * 2014-11-21 2017-08-31 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
JP6854762B2 (ja) * 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
KR102588426B1 (ko) 2015-06-15 2023-10-13 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 유도체
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
SG11201804210XA (en) 2015-11-20 2018-06-28 Mingsight Pharmaceuticals Inc Treatment of autoimmune disease
CN109715166A (zh) 2016-07-14 2019-05-03 深圳明赛瑞霖药业有限公司 癌症的治疗
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
US12304913B2 (en) 2018-11-14 2025-05-20 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN119684220A (zh) * 2024-12-13 2025-03-25 江苏宝众宝达药业股份有限公司 一种(2r,5r)-1,2,5-三甲基哌嗪的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060857A (zh) * 2000-08-10 2011-05-18 辉瑞意大利有限公司 具有激酶抑制剂活性的二环吡唑类、其制备方法和包含它们的药物组合物
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
BRPI0408486A (pt) * 2003-03-11 2006-04-04 Pharmacia Italia Spa derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os
CA2539549A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
WO2008125945A2 (en) 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c

Also Published As

Publication number Publication date
CN101675052A (zh) 2010-03-17
US8114871B2 (en) 2012-02-14
JP5404601B2 (ja) 2014-02-05
CN104370914B (zh) 2018-09-07
IL201104A0 (en) 2010-05-17
WO2008125945A3 (en) 2009-03-12
US8999981B2 (en) 2015-04-07
AU2008237660B2 (en) 2011-12-22
WO2008125945A2 (en) 2008-10-23
EP2195321B1 (en) 2016-10-19
CN104356136A (zh) 2015-02-18
AU2008237660A1 (en) 2008-10-23
HK1207068A1 (en) 2016-01-22
KR101113387B1 (ko) 2012-04-23
US20120108588A1 (en) 2012-05-03
US20100249128A1 (en) 2010-09-30
CA2683695A1 (en) 2008-10-23
HK1207067A1 (en) 2016-01-22
EP2195321A2 (en) 2010-06-16
JP2010523643A (ja) 2010-07-15
KR20090130039A (ko) 2009-12-17
MX2009010951A (es) 2009-10-29
CA2683695C (en) 2013-06-18
CN104370914A (zh) 2015-02-25

Similar Documents

Publication Publication Date Title
IL201104A (en) Compound 3-Amido-Pyrolo [3,4- c] Phospholase-5 (h1, h4, h6) Carbaldehyde for use as a protein kinase c inhibitor, a pharmaceutical composition comprising the compound and the use of a compound in the preparation of a drug
IL177283A (en) Pyrazolopyrimidine compounds, their use in the preparation of medicines and pharmaceuticals containing them
IL196775A (en) Annotations 4,2-Bis (3-Methyl-Morpholine-4-Yl) -7-Phenyl-Pyrido [3,2- d] Pyrimidine, Containing and Using Pharmaceuticals as Drugs and Drug Manufacturing
IL183360A (en) 12-aryl prostaglandin analogs, compositions comprising them and their use in the preparation of medicaments
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
AP2009004958A0 (en) 3-amino-pyrrolo [3,4-C] pyrazole - 5 (1H, 4H, 6H) carbaldehyde derivatives as PKC inhibitors
IL193141A (en) Compounds including pyrrolo [2,3– d] pyrimidine 7 - yl and sulphamate, pharmaceuticals and their use
IL201176A (en) 4-amino-1-h-pyrazolo [3,4- d] pyrimidine-3-ram-phenyl, a pharmaceutical containing them and their use in the preparation of a drug
IL194835A (en) History of cyclohexylpyrazole-lactam, an intermediate substance for their use in the preparation of drugs
EP1984370A4 (en) PROTEIN KINASE ACTIVITY INHIBITING IMIDAZOPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL221770A (en) Edamantyl acetamide derivatives, the pharmaceutical composition containing them and its use in the preparation of a drug
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
IL195528A (en) Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material
IL228952B (en) Use of preparations containing iron citrate to prepare drugs to reduce serum phosphate levels
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
ZA201100429B (en) Novel imidazo [1,2-a]pyrimidine derivatives,method for the preparation thereof,use thereof as medicaments,pharmaceutical compositions and novel use in particular as met inhibitors
IL192053A (en) 2-Admentiluria derivatives as selective inhibitors of 1hsd-β11 and their use in drug preparation
IL202379A (en) Benzoxaborols, their pharmaceutical preparations and their use in the preparation of bacteria to inhibit the growth of germs
IL204264A (en) Pyridine derivatives - 2 - moiety - amino - 1, 2, 4 - theadiazole, a method for their preparation, useful intermediates in their preparation, pharmaceutical preparations containing them and their use in the preparation of drugs
IL208355A (en) Annotations 7,3-Dihydroporin-6,2-Discussion, Processes for their Preparation, Pharmaceutical Preparations Containing them and their Use in Medication Preparation
IL194678A (en) Kinase inhibitors, pharmaceutical preparations containing them and their uses in the preparation of a drug for the treatment of cancer in mammals
IL187391A0 (en) Thiazole derivatives, their preparation and use and pharmaceutical compositions containing them
IL210708A0 (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed